194 related articles for article (PubMed ID: 8529281)
1. Schedule-dependent synergism of taxol or taxotere with edatrexate against human breast cancer cells in vitro.
Chou TC; Otter GM; Sirotnak FM
Cancer Chemother Pharmacol; 1996; 37(3):222-8. PubMed ID: 8529281
[TBL] [Abstract][Full Text] [Related]
2. Schedule-dependent synergism of edatrexate and cisplatin in combination in the A549 lung-cancer cell line as assessed by median-effect analysis.
Perez EA; Hack FM; Webber LM; Chou TC
Cancer Chemother Pharmacol; 1993; 33(3):245-50. PubMed ID: 8269606
[TBL] [Abstract][Full Text] [Related]
3. Paclitaxel combination therapy in the treatment of metastatic breast cancer: a review.
Holmes FA
Semin Oncol; 1996 Oct; 23(5 Suppl 11):46-56. PubMed ID: 8893900
[TBL] [Abstract][Full Text] [Related]
4. Computerized quantitation of synergism and antagonism of taxol, topotecan, and cisplatin against human teratocarcinoma cell growth: a rational approach to clinical protocol design.
Chou TC; Motzer RJ; Tong Y; Bosl GJ
J Natl Cancer Inst; 1994 Oct; 86(20):1517-24. PubMed ID: 7932806
[TBL] [Abstract][Full Text] [Related]
5. Omega-6 polyunsaturated fatty acid gamma-linolenic acid (18:3n-6) enhances docetaxel (Taxotere) cytotoxicity in human breast carcinoma cells: Relationship to lipid peroxidation and HER-2/neu expression.
Menendez JA; Ropero S; Lupu R; Colomer R
Oncol Rep; 2004 Jun; 11(6):1241-52. PubMed ID: 15138562
[TBL] [Abstract][Full Text] [Related]
6. In vitro comparative evaluation of trastuzumab (Herceptin) combined with paclitaxel (Taxol) or docetaxel (Taxotere) in HER2-expressing human breast cancer cell lines.
Merlin JL; Barberi-Heyob M; Bachmann N
Ann Oncol; 2002 Nov; 13(11):1743-8. PubMed ID: 12419746
[TBL] [Abstract][Full Text] [Related]
7. Pharmacological and small interference RNA-mediated inhibition of breast cancer-associated fatty acid synthase (oncogenic antigen-519) synergistically enhances Taxol (paclitaxel)-induced cytotoxicity.
Menendez JA; Vellon L; Colomer R; Lupu R
Int J Cancer; 2005 May; 115(1):19-35. PubMed ID: 15657900
[TBL] [Abstract][Full Text] [Related]
8. Schedule-dependent synergism and antagonism between paclitaxel and methotrexate in human carcinoma cell lines.
Kano Y; Akutsu M; Tsunoda S; Furuta M; Yazawa Y; Ando J
Oncol Res; 1998; 10(7):347-54. PubMed ID: 10063968
[TBL] [Abstract][Full Text] [Related]
9. Quantitation of the synergistic interaction of edatrexate and cisplatin in vitro.
Chou TC; Tan QH; Sirotnak FM
Cancer Chemother Pharmacol; 1993; 31(4):259-64. PubMed ID: 8422687
[TBL] [Abstract][Full Text] [Related]
10. Synergism of cytotoxic effects of vinorelbine and paclitaxel in vitro.
Budman DR; Calabro A; Wang LG; Liu XM; Stiel L; Adams LM; Kreis W
Cancer Invest; 2000; 18(8):695-701. PubMed ID: 11107439
[TBL] [Abstract][Full Text] [Related]
11. In vitro evaluation of schedule-dependent interactions between docetaxel and doxorubicin against human breast and ovarian cancer cells.
Zeng S; Chen YZ; Fu L; Johnson KR; Fan W
Clin Cancer Res; 2000 Sep; 6(9):3766-73. PubMed ID: 10999771
[TBL] [Abstract][Full Text] [Related]
12. In vitro search for synergy and antagonism: evaluation of docetaxel combinations in breast cancer cell lines.
Budman DR; Calabro A
Breast Cancer Res Treat; 2002 Jul; 74(1):41-6. PubMed ID: 12150451
[TBL] [Abstract][Full Text] [Related]
13. Docetaxel in breast cancer and a rationale for combination therapy.
Hortobágyi G
Oncology (Williston Park); 1997 Jun; 11(6 Suppl 6):11-5. PubMed ID: 9213321
[TBL] [Abstract][Full Text] [Related]
14. Taxoids in combination chemotherapy for metastatic breast cancer.
Dieras V; Fumoleau P; Bourgeois H; Misset JL; Azli N; Pouillart P
Anticancer Drugs; 1996 Aug; 7 Suppl 2():47-52. PubMed ID: 8862712
[TBL] [Abstract][Full Text] [Related]
15. 'Rings' of F-actin form around the nucleus in cultured human MCF7 adenocarcinoma cells upon exposure to both taxol and taxotere.
Rosenblum MD; Shivers RR
Comp Biochem Physiol C Toxicol Pharmacol; 2000 Jan; 125(1):121-31. PubMed ID: 11790336
[TBL] [Abstract][Full Text] [Related]
16. [Pharmacological study of weekly docetaxel in patients with metastatic breast cancer].
Kim Y; Takatsuka Y; Gotoh K; Hasegawa S; Aritake N; Kan K; Fukunaga M; Touno T; Oozato H; Imamoto H; Yamazaki K; Maruyama H
Gan To Kagaku Ryoho; 1999 Sep; 26(10):1437-41. PubMed ID: 10500531
[TBL] [Abstract][Full Text] [Related]
17. Docetaxel alone or orally combined with 5-fluorouracil and its derivatives: effects on mouse mammary tumor cell line MM2 in vitro and in vivo.
Takeda Y; Yoshizaki I; Nonaka Y; Yanagie H; Matsuzawa A; Eriguchi M
Anticancer Drugs; 2001 Sep; 12(8):691-8. PubMed ID: 11604557
[TBL] [Abstract][Full Text] [Related]
18. Schedule-dependent interactions between vinorelbine and paclitaxel in human carcinoma cell lines in vitro.
Kano Y; Akutsu M; Suzuki K; Ando J; Tsunoda S
Breast Cancer Res Treat; 1999 Jul; 56(1):79-90. PubMed ID: 10517345
[TBL] [Abstract][Full Text] [Related]
19. Interaction between Herceptin and taxanes.
Diéras V; Beuzeboc P; Laurence V; Pierga JY; Pouillart P
Oncology; 2001; 61 Suppl 2():43-9. PubMed ID: 11694787
[TBL] [Abstract][Full Text] [Related]
20. Docetaxel enhances the cytotoxicity of tetrahydropyranyladriamycin in a sequence-dependent manner.
Egawa T; Kubota T; Furukawa T; Otani Y; Watanabe M; Furukawa T; Kumai K; Kitajima M
Anticancer Res; 2001; 21(4A):2597-600. PubMed ID: 11724327
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
